Ballarin R, Spaggiari M, Cautero N, Ruvo ND, Montalti R, Longo C, Pecchi A, Giacobazzi P, Marco GD, D’Amico G, Gerunda GE, Benedetto FD. Pancreatic metastases from renal cell carcinoma: The state of the art. World J Gastroenterol 2011; 17(43): 4747-4756 [PMID: 22147975 DOI: 10.3748/wjg.v17.i43.4747]
Corresponding Author of This Article
Roberto Ballarin, MD, Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, No. 71, Via del Pozzo, 41100 Modena, Italy. ballarinroberto@hotmail.com
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 21, 2011; 17(43): 4747-4756 Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4747
Pancreatic metastases from renal cell carcinoma: The state of the art
Roberto Ballarin, Mario Spaggiari, Nicola Cautero, Nicola De Ruvo, Roberto Montalti, Cristina Longo, Anna Pecchi, Patrizia Giacobazzi, Giuseppina De Marco, Giuseppe D’Amico, Giorgio Enrico Gerunda, Fabrizio Di Benedetto
Roberto Ballarin, Mario Spaggiari, Nicola Cautero, Nicola De Ruvo, Roberto Montalti, Cristina Longo, Giuseppe D’Amico, Giorgio Enrico Gerunda, Fabrizio Di Benedetto, Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, 41100 Modena, Italy
Anna Pecchi, Department of Radiology, University of Modena and Reggio Emilia, 41100 Modena, Italy
Patrizia Giacobazzi, Giuseppina De Marco, Unit of Oncological Radiotherapy, University of Modena and Reggio Emilia, 41100 Modena, Italy
Author contributions: Ballarin R was involved in the conception of the editorial, was primary writer of the manuscript, performed manuscript editing and manuscript review; Spaggiari M, Cautero N, De Ruvo N, Montalti R, Longo C, Pecchi A, Giacobazzi P, De Marco G, D’Amico G, Gerunda GE and Di Benedetto F reviewed the manuscript and contributed to manuscript preparation.
Correspondence to: Roberto Ballarin, MD, Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, No. 71, Via del Pozzo, 41100 Modena, Italy. ballarinroberto@hotmail.com
Telephone: +39-059-4223683 Fax: +39-059-4223765
Received: April 7, 2011 Revised: June 15, 2011 Accepted: June 22, 2011 Published online: November 21, 2011
Abstract
Pancreatic metastases are rare, with a reported incidence varying from 1.6% to 11% in autopsy studies of patients with advanced malignancy. In clinical series, the frequency of pancreatic metastases ranges from 2% to 5% of all pancreatic malignant tumors. However, the pancreas is an elective site for metastases from carcinoma of the kidney and this peculiarity has been reported by several studies. The epidemiology, clinical presentation, and treatment of pancreatic metastases from renal cell carcinoma are known from single-institution case reports and literature reviews. There is currently very limited experience with the surgical resection of isolated pancreatic metastasis, and the role of surgery in the management of these patients has not been clearly defined. In fact, for many years pancreatic resections were associated with high rates of morbidity and mortality, and metastatic disease to the pancreas was considered to be a terminal-stage condition. More recently, a significant reduction in the operative risk following major pancreatic surgery has been demonstrated, thus extending the indication for these operations to patients with metastatic disease.
